COMMUNIQUÉS West-GlobeNewswire

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
16/07/2025
Company Announcement Net sales of DARZALEX ® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, [...]
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
16/07/2025
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader [...]
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
16/07/2025
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis [...]
Global POISE Study Reaches Milestone of 600 Orthopedic Implants in Pediatric Patients, Advancing Research on the Safety and Efficacy of OrthoPediatrics® Products
16/07/2025
WARSAW, Ind., July 16, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced a [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/07/2025
WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
16/07/2025
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’ [...]
Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call
16/07/2025
DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial [...]
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
16/07/2025
CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
CVRx Announces Positive News on Outpatient Payment for Barostim
16/07/2025
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to [...]
Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025
16/07/2025
TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 [...]
Jaya Biosciences Receives Patent Notices of Allowance in Japan, China, and Singapore for Novel Methods of Treating Neurological Diseases, including Alzheimer’s, Further Strengthening its Global Intellectual Property Portfolio
16/07/2025
- Patent allowances in Japan, China and Singapore support Jaya Biosciences’ commitment to addressing unmet needs in neurodegeneration in global markets - SOUTH SAN FRANCISCO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- [...]
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
16/07/2025
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo - - Additional [...]
Qualigen Granted New Patents Covering 25 Countries
16/07/2025
CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an update on patents granted in the first six months of 2025. The patent is [...]
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
16/07/2025
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30 [...]
Vantive and Innovative Renal Care Enter into a Long-Term Agreement Focused on Enhanced Use of Technology to Expand Home Dialysis Therapies
16/07/2025
Collaboration Aims to Expand Peritoneal Dialysis (PD) Access, Enable Greater Connection Between Patients and Care Teams, and Optimize Home Dialysis Care Delivery DEERFIELD, Ill. and FRANKLIN, Tenn., July 16, 2025 (GLOBE [...]
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
16/07/2025
Additional complete response (CR) observed in patient with multiple tumors Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19 [...]
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
16/07/2025
• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on [...]
ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes
16/07/2025
LOS ANGELES, July 16, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, announced today that its 2024 Annual Report has been posted to the company’s official website [...]
La nouvelle science des superhumains : le système d’IA BioSport™ libère le potentiel caché des athlètes
16/07/2025
Grâce à des conseillers d’élite, à une génomique de pointe et à une IA en temps réel, la plateforme de santé sportive cible les complications cardiaques, les blessures dues au surmenage, les sélections d’équipe [...]

Pages